Novartis Acquires DTx Pharma for ~$1B to Expands Neuroscience Pipeline
Shots:
- DTx Pharma will receive $500M up front & additional fee of ~$500M upon completion of pre-specified milestones. The acquisition will expand Novartis' capabilities in RNA-based therapies & adds DTx’s FALCON platform to the Novartis siRNA toolkit enabling the delivery and activity of siRNA therapeutics to tissues beyond the liver
- The acquisition also incl. DTx-1252 for the CMT1A and two additional preclinical programs for other neuroscience indications. Novartis obtains full rights to the FALCON platform
- DTx’s DTx-1252 is currently in preclinical development & received ODD from the US FDA for CMT1A. DTx-1252 is designed to target the “root cause” of the disorder by tackling the overexpression of a protein called PMP22
Ref: Novartis | Image: Novartis
Related News:- Novartis Entered into an Agreement to Acquire Chinook Therapeutics for ~$3.5B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
